SCHEMBL4884903

SCHEMBL4884903

CCC(C)c1cc(C(C)(C)C)c(O)c(S(=O)(=O)Cl)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 3/20 0.38
CYP2D6 P10635 2/20 0.38
HDAC4 P56524 1/20 0.38
HDAC2 Q92769 1/20 0.38
HDAC8 Q9BY41 1/20 0.38
TSHR P16473 3/20 0.37
CYP3A4 P08684 2/20 0.37
CYP2C9 P11712 2/20 0.37
CYP2C19 P33261 2/20 0.37
ALDH1A1 P00352 4/20 0.36
USP2 O75604 2/20 0.36
GAA P10253 2/20 0.36
PKM P14618 1/20 0.36
HPGD P15428 1/20 0.36
ALOX15 P16050 1/20 0.36
HSD17B10 Q99714 1/20 0.36
LMNA P02545 2/20 0.35
RECQL P46063 1/20 0.35
CA2 P00918 2/20 0.34
CA1 P00915 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4890157 0.85 ALDH1A1 (0.43) CYP1A2CYP2D6HDAC4HDAC2HDAC8
SCHEMBL144821 0.82 CA2 (0.50) CYP1A2CYP2D6TSHRCYP3A4CYP2C9
SCHEMBL2951999 0.78 CYP1A2 (0.44) CYP1A2CYP2D6HDAC4HDAC2HDAC8
SCHEMBL12626206 0.76 CYP2C9 (0.52) CYP1A2CYP2D6HDAC4HDAC2HDAC8
SCHEMBL30337273 0.75 HSPA5 (0.56) CYP1A2CYP2D6HDAC4HDAC2HDAC8
SCHEMBL99080 0.75 CYP2C9 (0.47) CYP1A2CYP2D6HDAC4HDAC2HDAC8
SCHEMBL22190072 0.75 CYP1A2 (0.53) CYP1A2CYP2D6HDAC4HDAC2HDAC8
SCHEMBL10778785 0.75 HSPA5 (0.56) CYP1A2CYP2D6HDAC4HDAC2HDAC8
SCHEMBL4890178 0.73 MCL1 (0.47) LMNACA2CA1MEN1KMT2A
SCHEMBL4896279 0.73 SLC22A12 (0.52) TSHRHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080255240-A1 Sulfonamide Derivatives NOVO NORDISK A/S (DK) 2008-10-16 US disclosed
EP-1756025-A1 SULFONAMIDE DERIVATIVES NOVO NORDISK A/S (DK) 2007-02-28 EP disclosed
WO-2005105712-A1 SULFONAMIDE DERIVATIVES NOVO NORDISK A/S (DK) 2005-11-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255240-A1 Sulfonamide Derivatives FABP4, SQOR, CS CYP1A2 1519/4885CYP2D6 2134/4885HDAC4 255/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.